151 related articles for article (PubMed ID: 21998341)
1. "Research use only" reagents: is there an imperative for increased FDA oversight?
O'Leary TJ
Clin Chem; 2011 Dec; 57(12):1681-3. PubMed ID: 21998341
[No Abstract] [Full Text] [Related]
2. FDA and CLIA oversight of advanced diagnostics and biomarker tests.
Terry SF
Genet Test Mol Biomarkers; 2010 Jun; 14(3):285-7. PubMed ID: 20578940
[No Abstract] [Full Text] [Related]
3. Modification of In Vitro Diagnostic Devices: Leveling the Playing Field.
Rychert J; Delgado JC; Genzen JR
Clin Chem; 2020 Jun; 66(6):760-762. PubMed ID: 32278318
[No Abstract] [Full Text] [Related]
4. FDA oversight of laboratory-developed tests: is it necessary, and how would it impact clinical laboratories?
Scott MG; Ashwood ER; Annesley TM; Leonard DG; Burgess MC
Clin Chem; 2013 Jul; 59(7):1017-22. PubMed ID: 23536512
[No Abstract] [Full Text] [Related]
5. Looming regulations and FDA oversight mean an uncertain reimbursement climate in 2016.
Wolf R
MLO Med Lab Obs; 2016 May; 48(5):26-7. PubMed ID: 27323455
[No Abstract] [Full Text] [Related]
6. FDA Announces Increased Oversight of Some Diagnostic Laboratory Tests.
Harris E
JAMA; 2024 Jun; 331(24):2071. PubMed ID: 38819803
[No Abstract] [Full Text] [Related]
7. FDA regulation of laboratory-developed diagnostic tests: protect the public, advance the science.
Sharfstein J
JAMA; 2015 Feb; 313(7):667-8. PubMed ID: 25560381
[No Abstract] [Full Text] [Related]
8. US Food and Drug Administration regulatory oversight of laboratory-developed tests: Commentary on the draft guidance.
Sidawy MK
Cancer Cytopathol; 2015 Oct; 123(10):573-5. PubMed ID: 26042383
[No Abstract] [Full Text] [Related]
9. FDA regulation of LDTs--an update.
Jones PM
MLO Med Lab Obs; 2015 Sep; 47(9):18-9. PubMed ID: 26495591
[No Abstract] [Full Text] [Related]
10. FDA announces plans to regulate LDTs.
Cancer Discov; 2014 Nov; 4(11):1250. PubMed ID: 25367935
[No Abstract] [Full Text] [Related]
11. FDA oversight of cell therapy clinical trials.
Au P; Hursh DA; Lim A; Moos MC; Oh SS; Schneider BS; Witten CM
Sci Transl Med; 2012 Aug; 4(149):149fs31. PubMed ID: 22932219
[TBL] [Abstract][Full Text] [Related]
12. FDA's framework for regulatory oversight of LDTs.
Pathak B; Terry SF
Genet Test Mol Biomarkers; 2014 Dec; 18(12):785-6. PubMed ID: 25469801
[No Abstract] [Full Text] [Related]
13. Pharmaceuticals and Medical Devices: FDA Oversight.
White RS;
Issue Brief Health Policy Track Serv; 2017 Dec; 2017():1-33. PubMed ID: 29361662
[No Abstract] [Full Text] [Related]
14. Does Increased Regulation of Laboratory-Developed Tests (LDTs) Make Sense? The Harms of Over-Regulation.
Hortin GL
J Appl Lab Med; 2024 May; 9(3):646-650. PubMed ID: 38332567
[No Abstract] [Full Text] [Related]
15. The ABCs of the FDA: A Primer on the Role of the United States Food and Drug Administration in Medical Device Approvals and IR Research.
Adamovich A; Park S; Siskin GP; Englander MJ; Mandato KD; Herr A; Keating LJ
J Vasc Interv Radiol; 2015 Sep; 26(9):1324-30. PubMed ID: 26189046
[TBL] [Abstract][Full Text] [Related]
16. Don’t Try This at Home: the FDA’s Restrictive Regulation of Home Testing Devices.
Baird S
Duke Law J; 2017 Nov; 67(2):383-426. PubMed ID: 29469551
[TBL] [Abstract][Full Text] [Related]
17. Point: The Need for Additional FDA Regulations in Laboratory Medicine.
Konnick EQ
J Appl Lab Med; 2024 Jan; 9(1):151-154. PubMed ID: 38167766
[No Abstract] [Full Text] [Related]
18. How will the FDA impact the laboratory developed test?
Davis J; Wentz J
Clin Lab Sci; 2007; 20(3):130-1. PubMed ID: 17691668
[No Abstract] [Full Text] [Related]
19. Counterpoint: Why the FDA Should Not Regulate Laboratory-Developed Tests.
Leung ML
J Appl Lab Med; 2024 Jan; 9(1):155-158. PubMed ID: 38167755
[No Abstract] [Full Text] [Related]
20. Tighter gene tests.
Fox J
Nat Biotechnol; 2008 Jul; 26(7):721. PubMed ID: 18612277
[No Abstract] [Full Text] [Related]
[Next] [New Search]
